Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
10.73
-0.37 (-3.33%)
At close: Jul 24, 2026, 4:00 PM EDT
10.94
+0.21 (1.96%)
Pre-market: Jul 27, 2026, 7:01 AM EDT
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $15.05M in the quarter ending March 31, 2026, a decrease of -9.50%. This brings the company's revenue in the last twelve months to $66.09M, up 45.04% year-over-year. In the year 2025, Intellia Therapeutics had annual revenue of $67.67M with 16.92% growth.
Revenue (ttm)
$66.09M
Revenue Growth
+45.04%
P/S Ratio
22.68
Revenue / Employee
$175,310
Employees
377
Market Cap
1.50B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.67M | 9.79M | 16.92% |
| Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
| Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
| Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
| Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
| Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
| Dec 31, 2019 | 43.10M | 12.67M | 41.63% |
| Dec 31, 2018 | 30.43M | 4.32M | 16.53% |
| Dec 31, 2017 | 26.12M | 9.64M | 58.49% |
| Dec 31, 2016 | 16.48M | 10.44M | 172.65% |
| Dec 31, 2015 | 6.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 420.69M |
| AnaptysBio | 232.39M |
| Xencor | 97.36M |
| AbCellera Biologics | 79.21M |
| Septerna | 72.26M |
| Recursion Pharmaceuticals | 66.41M |
| Vir Biotechnology | 65.50M |
| Maze Therapeutics | 20.00M |
NTLA News
- 11 days ago - Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research - TheFly
- 16 days ago - Intellia Therapeutics price target raised to $17 from $12 at Wedbush - TheFly
- 20 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Intellia Therapeutics rises 12.9% - TheFly
- 5 weeks ago - Intellia Therapeutics rises 10.7% - TheFly
- 6 weeks ago - Intellia Therapeutics presents additional results from Phase 3 HAELO trial - TheFly
- 6 weeks ago - Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - GlobeNewsWire
- 6 weeks ago - Intellia Therapeutics Transcript: AGM 2026 - Transcripts